Iris Gehrke

979 total citations
24 papers, 749 citations indexed

About

Iris Gehrke is a scholar working on Molecular Biology, Genetics and Immunology. According to data from OpenAlex, Iris Gehrke has authored 24 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Genetics and 6 papers in Immunology. Recurrent topics in Iris Gehrke's work include Chronic Lymphocytic Leukemia Research (16 papers), Wnt/β-catenin signaling in development and cancer (7 papers) and Cancer-related gene regulation (4 papers). Iris Gehrke is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Wnt/β-catenin signaling in development and cancer (7 papers) and Cancer-related gene regulation (4 papers). Iris Gehrke collaborates with scholars based in Germany, Canada and Switzerland. Iris Gehrke's co-authors include Karl‐Anton Kreuzer, Rajesh Kumar Gandhirajan, Michael Hallek, E. Schmitt, Peter Staib, Bernhard Kumle, Andreas Hochhaus, Salvatore Russo, Sebastian Birndt and Hinrich Bremer and has published in prestigious journals such as Blood, Clinical Cancer Research and European Journal of Cancer.

In The Last Decade

Iris Gehrke

23 papers receiving 734 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Iris Gehrke Germany 16 426 171 168 113 108 24 749
Géraldine Farjot France 12 569 1.3× 243 1.4× 258 1.5× 70 0.6× 448 4.1× 24 1.2k
S Seto Japan 13 238 0.6× 190 1.1× 207 1.2× 65 0.6× 116 1.1× 20 767
Dalibor Valík Czechia 18 474 1.1× 119 0.7× 300 1.8× 33 0.3× 155 1.4× 73 1.1k
Rajinder Singh India 8 182 0.4× 66 0.4× 199 1.2× 56 0.5× 374 3.5× 21 723
Fonda M. Newcomb United States 8 289 0.7× 39 0.2× 202 1.2× 115 1.0× 57 0.5× 12 601
Kathryn Mazina United States 14 426 1.0× 86 0.5× 159 0.9× 44 0.4× 40 0.4× 20 602
Mohammad Faranoush Iran 13 171 0.4× 136 0.8× 106 0.6× 28 0.2× 71 0.7× 96 585
Roberta Fedele Italy 16 207 0.5× 62 0.4× 165 1.0× 76 0.7× 103 1.0× 47 693
P. Brent Ferrell United States 17 325 0.8× 126 0.7× 264 1.6× 35 0.3× 341 3.2× 49 1.1k
Susan Bakke United States 11 816 1.9× 84 0.5× 711 4.2× 66 0.6× 123 1.1× 12 1.4k

Countries citing papers authored by Iris Gehrke

Since Specialization
Citations

This map shows the geographic impact of Iris Gehrke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Gehrke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Gehrke more than expected).

Fields of papers citing papers by Iris Gehrke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Gehrke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Gehrke. The network helps show where Iris Gehrke may publish in the future.

Co-authorship network of co-authors of Iris Gehrke

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Gehrke. A scholar is included among the top collaborators of Iris Gehrke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Gehrke. Iris Gehrke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bremer, Hinrich, Iris Gehrke, Andreas Hochhaus, et al.. (2020). The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 34(7). 1805–1815. 158 indexed citations
2.
Rosée, Paul La, Hinrich Bremer, Andreas Hochhaus, et al.. (2020). Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter hyperferritinämischer Inflammation. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 116(2). 138–145. 1 indexed citations
3.
Gehrke, Iris, et al.. (2014). On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells. Clinical Cancer Research. 20(18). 4861–4872. 61 indexed citations
4.
Gehrke, Iris, et al.. (2014). Angiopoietin-2/Tie2 Signaling in the Microenvironment of Chronic Lymphocytic Leukemia (CLL). 3(1). 6–18. 2 indexed citations
5.
Peiffer, Lukas, et al.. (2014). Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation. Journal of Cancer Research and Clinical Oncology. 140(8). 1283–1293. 18 indexed citations
6.
Gehrke, Iris, et al.. (2014). Angiogenic factors in chronic lymphocytic leukaemia (CLL): Where do we stand?. Critical Reviews in Oncology/Hematology. 93(3). 225–236. 16 indexed citations
7.
Patz, Michaela, Iris Gehrke, Julia Claasen, et al.. (2012). Comparison of the Effects of Two Kinase Inhibitors, Sorafenib and Dasatinib, on Chronic Lymphocytic Leukemia Cells. Oncology Research and Treatment. 35(7-8). 420–426. 9 indexed citations
8.
9.
Filipovich, Alexandra H., et al.. (2011). Physiological inhibitors of Wnt signaling. European Journal Of Haematology. 86(6). 453–465. 26 indexed citations
10.
Schmidt, Christina, et al.. (2011). Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL). Leukemia Research. 35(10). 1360–1366. 35 indexed citations
11.
Gehrke, Iris, et al.. (2011). A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: case report. Molecular Cytogenetics. 4(1). 8–8. 16 indexed citations
12.
13.
Gehrke, Iris, Rajesh Kumar Gandhirajan, Alexandra H. Filipovich, et al.. (2010). The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo. Clinical Cancer Research. 16(13). 3390–3398. 47 indexed citations
14.
Gehrke, Iris, et al.. (2010). Nitric Oxide–Donating Acetylsalicylic Acid Induces Apoptosis in Chronic Lymphocytic Leukemia Cells and Shows Strong Antitumor Efficacy In vivo. Clinical Cancer Research. 17(2). 286–293. 17 indexed citations
15.
Gandhirajan, Rajesh Kumar, Peter Staib, Iris Gehrke, et al.. (2010). Small Molecule Inhibitors of Wnt/β-Catenin/Lef-1 Signaling Induces Apoptosis in Chronic Lymphocytic Leukemia Cells In Vitro and In Vivo. Neoplasia. 12(4). 326–IN6. 92 indexed citations
16.
Gandhirajan, Rajesh Kumar, et al.. (2010). Wnt/β-Catenin/LEF-1 Signaling in Chronic Lymphocytic Leukemia (CLL): A Target for Current and Potential Therapeutic Options. Current Cancer Drug Targets. 10(7). 716–727. 25 indexed citations
17.
Filipovich, Alexandra H., et al.. (2010). Evidence for non‐functional Dickkopf‐1 (DKK‐1) signaling in chronic lymphocytic leukemia (CLL). European Journal Of Haematology. 85(4). 309–313. 13 indexed citations
18.
Gehrke, Iris, Rajesh Kumar Gandhirajan, & Karl‐Anton Kreuzer. (2009). Targeting the WNT/β-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options. European Journal of Cancer. 45(16). 2759–2767. 62 indexed citations
19.
Staib, Peter, Iris Gehrke, Rajesh Kumar Gandhirajan, et al.. (2008). Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. European Journal Of Haematology. 82(3). 165–175. 67 indexed citations
20.
Booy, Evan P., Dina Johar, Iris Gehrke, et al.. (2006). Monoclonal and bispecific antibodies as novel therapeutics. Archivum Immunologiae et Therapiae Experimentalis. 54(2). 85–101. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Géraldine Farjot Breakdown of academic impact, for papers by S Seto Breakdown of academic impact, for papers by Dalibor Valík Breakdown of academic impact, for papers by Rajinder Singh Breakdown of academic impact, for papers by Fonda M. Newcomb Breakdown of academic impact, for papers by Kathryn Mazina Breakdown of academic impact, for papers by Mohammad Faranoush Breakdown of academic impact, for papers by Roberta Fedele Breakdown of academic impact, for papers by P. Brent Ferrell Breakdown of academic impact, for papers by Susan Bakke
Rankless by CCL
2026